

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (gh-63) SITRAVATINIB MALATE


PRONUNCIATION sit" ra va' ti nib

THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Butanedioic acid, 2-hydroxy-, (2S)-, compd. with *N*-[3-fluoro-4-[[2-[5-[[2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-*b*]pyridin-7-yl]oxy]phenyl]-*N'*-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
2. *N*-(3-fluoro-4-[[2-(5-[[2-methoxyethyl)amino]methyl]pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yl]oxy]phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2S)-2-hydroxybutanedioate (1:1)

STRUCTURAL FORMULA



MOLECULAR FORMULA  $C_4H_6O_5 \cdot C_{33}H_{29}F_2N_5O_4S$

MOLECULAR WEIGHT 763.8

TRADEMARK None as yet

SPONSOR Mirati Therapeutics Inc.

CODE DESIGNATIONS MGCD516 malate salt

CAS REGISTRY NUMBER 2244864-88-6

UNII ZR2110H6XE

gbk